Philip J. Jewsbury

Discovery and Characterization of AZD6738, a Potent Inhibitor of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Kinase with Application as an Anticancer Agent

Kevin M. Foote, J. Willem M. Nissink, Thomas M. McGuire et al. · Journal of Medicinal Chemistry · 2018 · 331 citations · Full text

Medicine, Oncology, Pharmacology +16

Aurora kinase inhibitor nanoparticles target tumors with favorable therapeutic index in vivo

Susan Ashton, Young Ho Song, Elaine Cadogan et al. · Science Translational Medicine · 2016 · 220 citations

Pharmacy, Oncology, Pharmacology +17

Identification of Novel Purine and Pyrimidine Cyclin-Dependent Kinase Inhibitors with Distinct Molecular Interactions and Tumor Cell Growth Inhibition Profiles

Christine E. Arris, F. Thomas Boyle, A. Hilary Calvert et al. · Journal of Medicinal Chemistry · 2000 · 216 citations · Full text

Medicine, Medicinal Chemistry, Oncology +14

Discovery of 4-{4-[(3<i>R</i>)-3-Methylmorpholin-4-yl]-6-[1-(methylsulfonyl)cyclopropyl]pyrimidin-2-yl}-1<i>H</i>-indole (AZ20): A Potent and Selective Inhibitor of ATR Protein Kinase with Monotherapy in Vivo Antitumor Activity

Kevin M. Foote, Kevin Blades, Anna Cronin et al. · Journal of Medicinal Chemistry · 2013 · 215 citations · Full text

Medicine, Oncology, Pharmacology +13

Structure-based design of a potent purine-based cyclin-dependent kinase inhibitor

Thomas G. Davies, Johanne Bentley, Christine E. Arris et al. · Nature Structural Biology · 2002 · 214 citations

Pharmacy, Medicinal Chemistry, Molecular Biology +14